2160.HK
MicroPort CardioFlow Medtech Corporation [2160.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2160.HK Stock Summary
Top 10 Correlated ETFs
2160.HK
Top 10 Correlated Stocks
2160.HK
In the News
2160.HK Financial details
Company Rating
-
Market Cap
2.2B
Income
-511.42M
Revenue
302.69M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
592
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-7.39
Forward P/E
-
PEG
-0.42
P/S
13.4
P/B
1.22
P/C
-
P/FCF
-14.53
Quick Ratio
10.53
Current Ratio
12.82
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
141.73%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-16.98%
SMA50
7.32%
SMA100
25.71%
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
-16%
ROC
-0.1%
Gross Margin
65%
Oper. Margin
-113%
Profit Margin
-181%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.85-2.56
52W High
-
52W Low
-
RSI
49.25
Rel Volume
0.38
Avg Volume
4.35M
Volume
1.65M
Perf Week
9.76%
Perf Month
-18.18%
Perf Quarter
25%
Perf Half Y
20%
-
-
-
-
Beta
0.383
-
-
Volatility
0.03%, 0.13%
Prev Close
0%
Price
0.9
Change
0%
Company Profile
- Volume Average 4.35M
- Market Capitalization 2.2B
- Employee 592
- CEO Mr. Jeffrey R Lindstrom
- Headquarters Shanghai,CN
- IPO Date 2021-02-04
-
Website
https://www.cardioflowmedtech.com 
MicroPort CardioFlow Medtech Corporation, a medical device company, researches, develops, and commercializes transcatheter and surgical solutions for structural heart diseases in the People's Republic of China. It offers Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set to target aortic, mitral, tricuspid, and surgical valves, as well as procedural accessories. The company was founded in 2010 and is headquartered in Shanghai, China.
